is this why our bonus payout changed so dramatically for Mydayis....good luck getting that $1500....
Law360 (July 9, 2018, 7:22 PM EDT) -- The Patent Trial and Appeal Board agreed Friday to review the entirety of two Shire PLC patents covering its long-acting attention deficit hyperactivity disorder medication Mydayis, following a challenge from KVK-Tech Inc.
KVK, a generic and specialty drug company, has sufficiently alleged that U.S. Patent Nos. 9,173,857 and 8,846,100 could be found invalid based on a combination of prior art, the board said in instituting the America Invents Act review. Namely, the patents could be invalidated on a mix of Shire's Adderall XR label and a...
Law360 (July 9, 2018, 7:22 PM EDT) -- The Patent Trial and Appeal Board agreed Friday to review the entirety of two Shire PLC patents covering its long-acting attention deficit hyperactivity disorder medication Mydayis, following a challenge from KVK-Tech Inc.
KVK, a generic and specialty drug company, has sufficiently alleged that U.S. Patent Nos. 9,173,857 and 8,846,100 could be found invalid based on a combination of prior art, the board said in instituting the America Invents Act review. Namely, the patents could be invalidated on a mix of Shire's Adderall XR label and a...